$5.76
2.54% today
Nasdaq, Nov 12, 05:54 pm CET
ISIN
US0070251097
Symbol
ADTX

Aditx Therapeutics Inc Stock price

$5.91
-51.13 89.64% 1M
-196.36 97.08% 6M
-5,355.94 99.89% YTD
-10,404.22 99.94% 1Y
-83,167,994.09 100.00% 3Y
-4,316,599,994.09 100.00% 5Y
-11,435,599,994.09 100.00% 10Y
-11,435,599,994.09 100.00% 20Y
Nasdaq, Closing price Tue, Nov 11 2025
+0.20 3.50%
ISIN
US0070251097
Symbol
ADTX
Industry

Key metrics

Basic
Market capitalization
$3.0m
Enterprise Value
$7.3m
Net debt
$4.4m
Cash
$320.0k
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
296.3 | 0.1
EV/Sales
731.3 | 0.3
EV/FCF
negative
P/B
0.2
Financial Health
Equity Ratio
27.6%
Return on Equity
-455.0%
ROCE
-182.6%
ROIC
-
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$10.0k | $21.3m
EBITDA
$-21.7m | -
EBIT
$-22.1m | $-9.2m
Net Income
$-31.0m | $-804.4m
Free Cash Flow
$-22.6m
Growth (TTM | estimate)
Revenue
-97.0% | 16,255.4%
EBITDA
34.6% | -
EBIT
34.4% | 66.9%
Net Income
28.3% | -1,893.6%
Free Cash Flow
-15.4%
Margin (TTM | estimate)
Gross
-4,365.3%
EBITDA
-179,008.3% | -
EBIT
-182,748.8%
Net
-256,539.7% | -3,783.3%
Free Cash Flow
-186,854.6%
More
EPS
$-14.8
FCF per Share
$-7.1
Short interest
0.1%
Employees
26
Rev per Employee
$10.0k
Show more

Is Aditx Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.

Aditx Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Aditx Therapeutics Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Aditx Therapeutics Inc forecast:

Buy
75%
Hold
25%

Financial data from Aditx Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.01 0.01
97% 97%
100%
- Direct Costs 0.54 0.54
13% 13%
5,400%
-0.53 -0.53
253% 253%
-5,300%
- Selling and Administrative Expenses 18 18
0% 0%
184,200%
- Research and Development Expense 3.16 3.16
79% 79%
31,600%
-22 -22
35% 35%
-216,600%
- Depreciation and Amortization 0.45 0.45
21% 21%
4,500%
EBIT (Operating Income) EBIT -22 -22
34% 34%
-221,126%
Net Profit -31 -31
28% 28%
-310,400%

In millions USD.

Don't miss a Thing! We will send you all news about Aditx Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aditx Therapeutics Inc Stock News

Neutral
Business Wire
14 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on November 3, 2025, the Company's common stock will trade on a post-split ba...
Neutral
Business Wire
16 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has begun enrollment in their prospective clinical study evaluating the Mitomic® Endometriosis Test (MET™), a novel blood-based diagnostic designed to aid in th...
Neutral
PRNewsWire
23 days ago
-- Evofem Shareholders Did Not Approve the Merger with Aditxt -- -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales -- SAN DIEGO , Oct. 20, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) ("Evofem" or the "Company"), today announced that at a Special Meeting of Stockholders held this morning, its stockholders did not approve the proposal to a...
More Aditx Therapeutics Inc News

Company Profile

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Head office United States
CEO Amro Albanna
Employees 26
Founded 2017
Website aditxt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today